{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:35:02Z","timestamp":1793068502525,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Construction Project of Research Division of Children's Kidney Disease of Wuhan Children's Hospital","award":["2022FEYJS003"],"award-info":[{"award-number":["2022FEYJS003"]}]},{"name":"Knowledge and Innovation Project of Wuhan Science and Technology Bureau","award":["2023020201010197"],"award-info":[{"award-number":["2023020201010197"]}]},{"name":"Medical Science Research Project from Wuhan Municipal Health Commission","award":["WX23A53"],"award-info":[{"award-number":["WX23A53"]}]},{"name":"Hubei province health and family planning scientific research project","award":["WJ2023M149"],"award-info":[{"award-number":["WJ2023M149"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07481-6","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:34:14Z","timestamp":1784684054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of anti-rituximab antibodies on rituximab efficacy in children with frequently relapsing or steroid-dependent nephrotic syndrome"],"prefix":"10.1007","author":[{"given":"Daojing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-6855","authenticated-orcid":false,"given":"Xiaowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"7481_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY-h Chan","year":"2023","unstructured":"Chan EY-h, Yap DY-h, Colucci M et al (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"7481_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K et al (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"7481_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor\u2013dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033","journal-title":"Kidney Int"},{"key":"7481_CR4","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.006","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Gibson KL, Vivarelli M et al (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107:S241\u2013S289. https:\/\/doi.org\/10.1016\/j.kint.2024.11.006","journal-title":"Kidney Int"},{"key":"7481_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","volume":"24","author":"N Dunn","year":"2017","unstructured":"Dunn N, Juto A, Ryner M et al (2017) Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler 24:1224\u20131233. https:\/\/doi.org\/10.1177\/1352458517720044","journal-title":"Mult Scler"},{"key":"7481_CR6","doi-asserted-by":"publisher","unstructured":"Faustini F, Dunn N, Kharlamova N et al (2021) First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. Arthritis Res Ther 23. https:\/\/doi.org\/10.1186\/s13075-021-02589-6","DOI":"10.1186\/s13075-021-02589-6"},{"key":"7481_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","volume":"37","author":"Q Bertrand","year":"2021","unstructured":"Bertrand Q, Mignot S, Kwon T et al (2021) Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 37:357\u2013365. https:\/\/doi.org\/10.1007\/s00467-021-05069-w","journal-title":"Pediatr Nephrol"},{"key":"7481_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00467-020-04629-w","volume":"35","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Nishino T, Endo S et al (2020) Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:2003\u20132008. https:\/\/doi.org\/10.1007\/s00467-020-04629-w","journal-title":"Pediatr Nephrol"},{"key":"7481_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"12","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S et al (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr 12:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr"},{"key":"7481_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","volume":"10","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, Teisseyre M, Accinno M et al (2025) Anti-Rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy. Kidney Int Rep 10:2621\u20132629. https:\/\/doi.org\/10.1016\/j.ekir.2025.04.059","journal-title":"Kidney Int Rep"},{"key":"7481_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/a:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M et al (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 9:527\u2013534. https:\/\/doi.org\/10.1023\/a:1008265313133","journal-title":"Ann Oncol"},{"key":"7481_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"7481_CR13","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1080\/10428194.2019.1633632","volume":"60","author":"M Candelaria","year":"2019","unstructured":"Candelaria M, Gonz\u00e1lez DE, Delamain MT et al (2019) Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma 60:3375\u20133385. https:\/\/doi.org\/10.1080\/10428194.2019.1633632","journal-title":"Leuk Lymphoma"},{"key":"7481_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Gonzalez D, Fern\u00e1ndez G\u00f3mez FJ et al (2018) Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83\u2122, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol 81:515\u2013527. https:\/\/doi.org\/10.1007\/s00280-018-3524-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"7481_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1681\/ASN.V103529","volume":"10","author":"HK Yap","year":"1999","unstructured":"Yap HK, Cheung W, Murugasu B et al (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529\u2013537. https:\/\/doi.org\/10.1681\/ASN.V103529","journal-title":"J Am Soc Nephrol"},{"key":"7481_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","volume":"155","author":"F Saffari","year":"2022","unstructured":"Saffari F, Jafarzadeh A (2022) Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences. Indian J Med Res 155:335\u2013346. https:\/\/doi.org\/10.4103\/ijmr.IJMR_312_19","journal-title":"Indian J Med Res"},{"key":"7481_CR17","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","volume":"62","author":"C Wincup","year":"2023","unstructured":"Wincup C, Dunn N, Ruetsch-Chelli C et al (2023) Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Rheumatology (Oxford) 62:2601\u20132610. https:\/\/doi.org\/10.1093\/rheumatology\/keac608","journal-title":"Rheumatology (Oxford)"},{"key":"7481_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.55563\/clinexprheumatol\/ftira8","volume":"40","author":"I Oomen","year":"2022","unstructured":"Oomen I, Nassar-Sheikh Rashid A, Bouts AHM et al (2022) Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. Clin Exp Rheumatol 40:183\u2013190. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ftira8","journal-title":"Clin Exp Rheumatol"},{"key":"7481_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1532\/ijh97.04081","volume":"80","author":"T Toubo","year":"2004","unstructured":"Toubo T, Suga N, Ohga S, Nomura A, Onoe Y, Takada H et al (2004) Successful unrelated cord blood transplantation for Epstein-Barr virus-associated lymphoproliferative disease with hemophagocytic syndrome. Int J Hematol 80:458\u2013462. https:\/\/doi.org\/10.1532\/ijh97.04081","journal-title":"Int J Hematol"},{"key":"7481_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","volume":"7","author":"A Angeletti","year":"2022","unstructured":"Angeletti A, Bruschi M, Colucci M et al (2022) Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome. Kidney Int Rep 7:2509\u20132512. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.006","journal-title":"Kidney Int Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07481-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:59:40Z","timestamp":1786694380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07481-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":20,"alternative-id":["7481"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07481-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}